Anti-epileptogenic and Anti-convulsive Effects of Fingolimod in Experimental Temporal Lobe Epilepsy

Julika Pitsch, Julia C. Kuehn, Vadym Gnatkovsky, Johannes Alexander Müller, Karen M.J. van Loo, Marco de Curtis, Hartmut Vatter, Susanne Schoch, Christian E. Elger, Albert J. Becker

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Temporal lobe epilepsy (TLE) represents a devastating neurological condition, in which approximately 4/5 of patients remain refractory for anti-convulsive drugs. Epilepsy surgery biopsies often reveal the damage pattern of “hippocampal sclerosis” (HS) characterized not only by neuronal loss but also pronounced astrogliosis and inflammatory changes. Since TLE shares distinct pathogenetic aspects with multiple sclerosis (MS), we have here scrutinized therapeutic effects in experimental TLE of the immunmodulator fingolimod, which is established in MS therapy. Fingolimod targets sphingosine-phosphate receptors (S1PRs). mRNAs of fingolimod target S1PRs were augmented in two experimental post status epilepticus (SE) TLE mouse models (suprahippocampal kainate/pilocarpine). SE frequently induces chronic recurrent seizures after an extended latency referred to as epileptogenesis. Transient fingolimod treatment of mice during epileptogenesis after suprahippocampal kainate-induced SE revealed substantial reduction of chronic seizure activity despite lacking acute attenuation of SE itself. Intriguingly, fingolimod exerted robust anti-convulsive activity in kainate-induced SE mice treated in the chronic TLE stage and had neuroprotective and anti-gliotic effects and reduced cytotoxic T cell infiltrates. Finally, the expression profile of fingolimod target-S1PRs in human hippocampal biopsy tissue of pharmacoresistant TLE patients undergoing epilepsy surgery for seizure relief suggests repurposing of fingolimod as novel therapeutic perspective in focal epilepsies.

Original languageEnglish
Pages (from-to)1-16
Number of pages16
JournalMolecular Neurobiology
DOIs
Publication statusAccepted/In press - Jun 22 2018

Fingerprint

Temporal Lobe Epilepsy
Status Epilepticus
Kainic Acid
Seizures
Multiple Sclerosis
Epilepsy
Biopsy
Sphingosine
Pilocarpine
Partial Epilepsy
Sclerosis
Therapeutic Uses
Fingolimod Hydrochloride
Therapeutics
Phosphates
T-Lymphocytes
Messenger RNA
Pharmaceutical Preparations

Keywords

  • Disease-modifying therapy
  • Epileptogenesis
  • Experimental epilepsy models
  • Temporal lobe epilepsy
  • Video-EEG

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Pitsch, J., Kuehn, J. C., Gnatkovsky, V., Müller, J. A., van Loo, K. M. J., de Curtis, M., ... Becker, A. J. (Accepted/In press). Anti-epileptogenic and Anti-convulsive Effects of Fingolimod in Experimental Temporal Lobe Epilepsy. Molecular Neurobiology, 1-16. https://doi.org/10.1007/s12035-018-1181-y

Anti-epileptogenic and Anti-convulsive Effects of Fingolimod in Experimental Temporal Lobe Epilepsy. / Pitsch, Julika; Kuehn, Julia C.; Gnatkovsky, Vadym; Müller, Johannes Alexander; van Loo, Karen M.J.; de Curtis, Marco; Vatter, Hartmut; Schoch, Susanne; Elger, Christian E.; Becker, Albert J.

In: Molecular Neurobiology, 22.06.2018, p. 1-16.

Research output: Contribution to journalArticle

Pitsch, J, Kuehn, JC, Gnatkovsky, V, Müller, JA, van Loo, KMJ, de Curtis, M, Vatter, H, Schoch, S, Elger, CE & Becker, AJ 2018, 'Anti-epileptogenic and Anti-convulsive Effects of Fingolimod in Experimental Temporal Lobe Epilepsy', Molecular Neurobiology, pp. 1-16. https://doi.org/10.1007/s12035-018-1181-y
Pitsch, Julika ; Kuehn, Julia C. ; Gnatkovsky, Vadym ; Müller, Johannes Alexander ; van Loo, Karen M.J. ; de Curtis, Marco ; Vatter, Hartmut ; Schoch, Susanne ; Elger, Christian E. ; Becker, Albert J. / Anti-epileptogenic and Anti-convulsive Effects of Fingolimod in Experimental Temporal Lobe Epilepsy. In: Molecular Neurobiology. 2018 ; pp. 1-16.
@article{d3df0add0687425cb29d8c8c48a08180,
title = "Anti-epileptogenic and Anti-convulsive Effects of Fingolimod in Experimental Temporal Lobe Epilepsy",
abstract = "Temporal lobe epilepsy (TLE) represents a devastating neurological condition, in which approximately 4/5 of patients remain refractory for anti-convulsive drugs. Epilepsy surgery biopsies often reveal the damage pattern of “hippocampal sclerosis” (HS) characterized not only by neuronal loss but also pronounced astrogliosis and inflammatory changes. Since TLE shares distinct pathogenetic aspects with multiple sclerosis (MS), we have here scrutinized therapeutic effects in experimental TLE of the immunmodulator fingolimod, which is established in MS therapy. Fingolimod targets sphingosine-phosphate receptors (S1PRs). mRNAs of fingolimod target S1PRs were augmented in two experimental post status epilepticus (SE) TLE mouse models (suprahippocampal kainate/pilocarpine). SE frequently induces chronic recurrent seizures after an extended latency referred to as epileptogenesis. Transient fingolimod treatment of mice during epileptogenesis after suprahippocampal kainate-induced SE revealed substantial reduction of chronic seizure activity despite lacking acute attenuation of SE itself. Intriguingly, fingolimod exerted robust anti-convulsive activity in kainate-induced SE mice treated in the chronic TLE stage and had neuroprotective and anti-gliotic effects and reduced cytotoxic T cell infiltrates. Finally, the expression profile of fingolimod target-S1PRs in human hippocampal biopsy tissue of pharmacoresistant TLE patients undergoing epilepsy surgery for seizure relief suggests repurposing of fingolimod as novel therapeutic perspective in focal epilepsies.",
keywords = "Disease-modifying therapy, Epileptogenesis, Experimental epilepsy models, Temporal lobe epilepsy, Video-EEG",
author = "Julika Pitsch and Kuehn, {Julia C.} and Vadym Gnatkovsky and M{\"u}ller, {Johannes Alexander} and {van Loo}, {Karen M.J.} and {de Curtis}, Marco and Hartmut Vatter and Susanne Schoch and Elger, {Christian E.} and Becker, {Albert J.}",
year = "2018",
month = "6",
day = "22",
doi = "10.1007/s12035-018-1181-y",
language = "English",
pages = "1--16",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Humana Press Inc.",

}

TY - JOUR

T1 - Anti-epileptogenic and Anti-convulsive Effects of Fingolimod in Experimental Temporal Lobe Epilepsy

AU - Pitsch, Julika

AU - Kuehn, Julia C.

AU - Gnatkovsky, Vadym

AU - Müller, Johannes Alexander

AU - van Loo, Karen M.J.

AU - de Curtis, Marco

AU - Vatter, Hartmut

AU - Schoch, Susanne

AU - Elger, Christian E.

AU - Becker, Albert J.

PY - 2018/6/22

Y1 - 2018/6/22

N2 - Temporal lobe epilepsy (TLE) represents a devastating neurological condition, in which approximately 4/5 of patients remain refractory for anti-convulsive drugs. Epilepsy surgery biopsies often reveal the damage pattern of “hippocampal sclerosis” (HS) characterized not only by neuronal loss but also pronounced astrogliosis and inflammatory changes. Since TLE shares distinct pathogenetic aspects with multiple sclerosis (MS), we have here scrutinized therapeutic effects in experimental TLE of the immunmodulator fingolimod, which is established in MS therapy. Fingolimod targets sphingosine-phosphate receptors (S1PRs). mRNAs of fingolimod target S1PRs were augmented in two experimental post status epilepticus (SE) TLE mouse models (suprahippocampal kainate/pilocarpine). SE frequently induces chronic recurrent seizures after an extended latency referred to as epileptogenesis. Transient fingolimod treatment of mice during epileptogenesis after suprahippocampal kainate-induced SE revealed substantial reduction of chronic seizure activity despite lacking acute attenuation of SE itself. Intriguingly, fingolimod exerted robust anti-convulsive activity in kainate-induced SE mice treated in the chronic TLE stage and had neuroprotective and anti-gliotic effects and reduced cytotoxic T cell infiltrates. Finally, the expression profile of fingolimod target-S1PRs in human hippocampal biopsy tissue of pharmacoresistant TLE patients undergoing epilepsy surgery for seizure relief suggests repurposing of fingolimod as novel therapeutic perspective in focal epilepsies.

AB - Temporal lobe epilepsy (TLE) represents a devastating neurological condition, in which approximately 4/5 of patients remain refractory for anti-convulsive drugs. Epilepsy surgery biopsies often reveal the damage pattern of “hippocampal sclerosis” (HS) characterized not only by neuronal loss but also pronounced astrogliosis and inflammatory changes. Since TLE shares distinct pathogenetic aspects with multiple sclerosis (MS), we have here scrutinized therapeutic effects in experimental TLE of the immunmodulator fingolimod, which is established in MS therapy. Fingolimod targets sphingosine-phosphate receptors (S1PRs). mRNAs of fingolimod target S1PRs were augmented in two experimental post status epilepticus (SE) TLE mouse models (suprahippocampal kainate/pilocarpine). SE frequently induces chronic recurrent seizures after an extended latency referred to as epileptogenesis. Transient fingolimod treatment of mice during epileptogenesis after suprahippocampal kainate-induced SE revealed substantial reduction of chronic seizure activity despite lacking acute attenuation of SE itself. Intriguingly, fingolimod exerted robust anti-convulsive activity in kainate-induced SE mice treated in the chronic TLE stage and had neuroprotective and anti-gliotic effects and reduced cytotoxic T cell infiltrates. Finally, the expression profile of fingolimod target-S1PRs in human hippocampal biopsy tissue of pharmacoresistant TLE patients undergoing epilepsy surgery for seizure relief suggests repurposing of fingolimod as novel therapeutic perspective in focal epilepsies.

KW - Disease-modifying therapy

KW - Epileptogenesis

KW - Experimental epilepsy models

KW - Temporal lobe epilepsy

KW - Video-EEG

UR - http://www.scopus.com/inward/record.url?scp=85048877198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048877198&partnerID=8YFLogxK

U2 - 10.1007/s12035-018-1181-y

DO - 10.1007/s12035-018-1181-y

M3 - Article

SP - 1

EP - 16

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

ER -